Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Income from Continuing Operations (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Income from Continuing Operations data on record, last reported at 81318000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 72.68% year-over-year to 81318000.0; the TTM value through Dec 2025 reached 258757000.0, down 63.91%, while the annual FY2025 figure was 258757000.0, 63.91% down from the prior year.
  • Income from Continuing Operations reached 81318000.0 in Q4 2025 per CLDX's latest filing, down from 67044000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 13373000.0 in Q2 2021 and bottomed at 81318000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 37056950.0, with a median of 34325000.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: plummeted 169.23% in 2022, then increased 15.28% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 20175000.0 in 2021, then crashed by 31.29% to 26487000.0 in 2022, then plummeted by 63.5% to 43306000.0 in 2023, then decreased by 8.74% to 47092000.0 in 2024, then plummeted by 72.68% to 81318000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 81318000.0 in Q4 2025, 67044000.0 in Q3 2025, and 56599000.0 in Q2 2025.